NCT05416320

Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA)

A Pilot Study of Calcipotriol as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

• Status: Withdrawn
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this pilot study is to determine if calcipotriol shows potential to be an effective treatment for Central Centrifugal Cicatricial Alopecia (CCCA). This study aims to evaluate calcipotriol due to the possible anti-inflammatory effects that may affect the hair growth cycle.

Detailed description

Calcipotriol, a vitamin D analog, has been topically used to treat alopecia areata, a form of non-scarring autoimmune alopecia in several studies. It is possible that Vitamin D plays a role in sustaining the hair follicle's immune privilege through anti-inflammatory effects such as controlling Interferon gamma (IFN-γ) production. A recent study showed a significant decrease of vitamin D in Black patients with Central Centrifugal Cicatricial Alopecia (CCCA)"

Conditions

• Central Centrifugal Cicatricial Alopecia

Interventions

Type	Name	Description
DRUG	Calcipotriol	Subjects will use the topical formulation once daily on the scalp. The subjects will use the treatment for a total of 6 months.
DRUG	Subject's already prescribed drug	Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.

Timeline

• Start date: 2023-08-01
• Primary completion: 2023-11-01
• Completion: 2023-12-01
• First posted: 2022-06-13
• Last updated: 2023-08-31

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study